Overview

Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

Status:
Completed
Trial end date:
2018-03-19
Target enrollment:
0
Participant gender:
All
Summary
This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Alcaftadine
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

-Patients with itching associated with allergic conjunctivitis.

Exclusion Criteria:

-Patients with hypersensitivity to Lastacaft® or its components.